Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure11A complete list of the members of the Latanoprost and Unoprostone Study Group is at the end of this article.

Jampel, Henry D.; Bacharach, Jason; Sheu, Wang Pui; Wohl, Lisa G.; Solish, Alfred M.; Christie, William C.

doi:10.1016/s0002-9394(02)01820-2

Cited by 32 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prospective studies that compared the efficacy of unoprostone with that of latanoprost for 8 or 12 weeks were performed by many investigators. 5 – 8 , 18 Both unoprostone and latanoprost were found to reduce IOP; however, unoprostone was less effective than latanoprost in patients with either POAG or ocular hypertension. Sponsel et al reported that there were no significant differences between unoprostone and latanoprost in MD or PSD using the 10-2 program (Humphrey Visual Field Analyzer), but after 4 weeks of treatment, the MD of the unoprostone group, using frequency-doubling technology, was improved by 1.7 dB over the pretreatment value.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study

Takemoto¹,

Higashide²,

Saito³

et al. 2017

OPTH

View full text Add to dashboard Cite

PurposeWe conducted a prospective study in patients with normal-tension glaucoma (NTG) who received either isopropyl unoprostone or latanoprost. We compared the drugs in terms of their effects on intraocular pressure (IOP) and visual field loss progression over a 3-year period.Study designProspective, randomized controlled study.MethodsWe enrolled 48 patients with newly diagnosed NTG at Kanazawa University Hospital. Eligible patients were randomly allocated (1:1) to receive either unoprostone or latanoprost ophthalmic solutions. The primary outcomes were IOP changes and visual field deterioration within 36 months. Visual field changes were analyzed: the cumulative survival rates were calculated in terms of mean deviation, pattern standard deviation, and total deviation of the upper or lower hemi-visual field, each visual field sector, and guided progression analysis. In addition, we evaluated the progression of glaucomatous optic disc changes using fundus photography and confocal scanning laser ophthalmoscopy.ResultsThe mean pretreatment IOP was 15.0±2.4 mmHg in the Unoprostone group and 15.2±1.9 mmHg in the Latanoprost group. The mean IOP during the treatment period was 13.7±2.3 mmHg in the Unoprostone group and 13.0±1.8 mmHg in the Latanoprost group. In both groups, the IOP decreased significantly (p<0.001) from baseline after treatment. The posttreatment IOP values were significantly lower in the Latanoprost group than in the Unoprostone group (p=0.023). Regarding the 3-year cumulative survival rate of visual field loss progression, there were no significant differences between groups in any parameters of the visual field or guided progression analysis. There were no significant differences between groups in disc changes.ConclusionsNo significant differences were found between groups with regard to the visual field and structural progression in patients with NTG, although unoprostone was less effective than latanoprost in lowering the IOP.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Latanoprost conferred a significantly greater reduction in IOP than unoprostone after 3 years of treatment. Our study period of 3 years is the longest among all of the reports mentioned so far, 5 – 8 , 18 all of which compared IOP reduction between groups for a period of 8–12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study

Takemoto¹,

Higashide²,

Saito³

et al. 2017

OPTH

View full text Add to dashboard Cite

show abstract

“…[63] When used in monotherapy, Unoprostone provided a clinically significant IOP-lowering effect, equivalent to that of betaxolol but not to those of timolol and latanoprost. [6465] However, in another study, an aqueous solution of 0.12% unoprostone isopropyl, applied topically to the eye twice daily for six weeks, was as effective as 0.5% timolol in maintaining control of IOP in subjects with chronic open angle glaucoma or ocular hypertension. [66] In a six-month study, it was found that unoprostone isopropyl beneficially provides additive IOP lowering effect to topical β-blocker in patients with primary open angle glaucoma.…”

Section: β Blockersmentioning

confidence: 99%

Recent advances in pharmacotherapy of glaucoma

et al. 2008

View full text Add to dashboard Cite

Glaucoma is a slow progressive degeneration of the retinal ganglion cells (RGCs) and the optic nerve axons, leading to irreversible blindness if left undiagnosed and untreated. Although increased intraocular pressure is a major risk factor of glaucoma, other factors include increased glutamate levels, alterations in nitric oxide (NO) metabolism, vascular alterations and oxidative damage caused by reactive oxygen species. Glaucoma is the second leading cause of blindness globally, accounting for 12.3% of the total blindness. Glaucoma has been broadly classified as primary or secondary open-angle or angle-closure glaucoma. The primary goal in management of glaucoma is to prevent the risk factor, especially elevated intraocular pressure (IOP), using medications, laser therapy or conventional surgery. The first-line treatment of glaucoma usually begins with the use of a topical selective or nonselective blocker or a prostaglandin analog. Second-line drugs of choice include alpha-agonists and topical carbonic anhydrase inhibitors. Cholinergic agonists are considered third-line treatment options. When a single therapy is not sufficient to lower the IOP, a combination therapy is indicated. To enhance the patient compliance, drug delivery systems like electronic devices, ocular inserts, tansdermal and mechanical drug delivery systems have been developed. Use of viscoelastic agents in ophthalmic formulations, emulsions and soluble ophthalmic drug inserts (SODI) enhance patience compliance and ocular drug delivery in patients in long-term glaucoma therapy. For patients who do not respond to antiglaucoma medications, laser trabeculoplasty and incisional surgery are recommended. Several nutrients and botanicals hold promise for the treatment of glaucoma, but most studies are preliminary, and larger, controlled studies are required. Future directions for the development of a novel therapy glaucoma may target glutamate inhibition, NMDA receptor blockade, exogenously applied neurotrophins, open channel blockers, antioxidants, protease inhibitors and gene therapy.

show abstract

Competition in the Pharmaceutical Drug Development

Tyrchan

Giordanetto

2012

Analogue‐Based Drug Discovery III

View full text Add to dashboard Cite

Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure11A complete list of the members of the Latanoprost and Unoprostone Study Group is at the end of this article.

Cited by 32 publications

References 24 publications

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study

Intraocular pressure and visual field changes in normal-tension glaucoma patients treated using either unoprostone or latanoprost: a prospective comparative study

Recent advances in pharmacotherapy of glaucoma

Competition in the Pharmaceutical Drug Development

Contact Info

Product

Resources

About